Pharmacokinetics. Other and unspecified diseases of pulp and periapical tissues
Conditions
Interventions
Intervention 1: In control group : Prescribed 2 capsules orally 1 hour before treatment as placebo. Intervention 2: Novafen group: Prescribed 2 200 mg capsules orally 1 hour befor treatment. Intervent
Treatment - Drugs
In control group : Prescribed 2 capsules orally 1 hour before treatment as placebo
Novafen group: Prescribed 2 200 mg capsules orally 1 hour befor treatment
Gelofen group: Prescribed 2 200 mg capsules orally 1 hour befor treatment
Sponsors
Babol University of Medical Sciences
Eligibility
Sex/Gender
All
Age
18 Years to 64 Years
Inclusion criteria
Inclusion criteria: Inclusion criteria: 1.The patient should be able to read , understand and complete the consent form; 2.Patient's consent form has been completed; 3.Teeth with a live pulp that do not have a peri-apical lesion should have been evaluated. Exclusion criteria : 1.Pregnancy; 2.Hypersensitivity to NSAIDs and Sulfonamides; 3.History of asthma associated with nasal polyps; 4.History of chronic use of analgesics or sedatives; 5.Alcohol abuse; 6.Patients with uncontrolled hypertension; 7.Diabetes mellitus; 8.Renal disease, CNS disease, heart disease and liver dysfunction; 9.Cancer or major anomalies confirmed by clinical examinations or laboratory findings; 10.Aged less than 18 and more than 65; 11.Pregnancy or breastfeeding; 12.Analgesic use less than 12 hours to the beginning of the study.
Exclusion criteria
Exclusion criteria:
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Pain. Timepoint: One hour before treatment. Method of measurement: 4,8,12,24,48. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactDr.Mohammad Kashefi Nejad
Babol Univesity Of Medical Sciences
Outcome results
None listed